This is Takura
Takura is an early stage developer of biopharma companies committed to put novel cell- and gene therapies into clinical practice.
Built on a strong engagement in the Nordic research and start-up ecosystem – we transform scientific ideas into products and drive access to patients.
We found, we fund and we build
The first step from a scientific idea into a progressive start-up is often a big hurdle in the world of medicine. Cell and gene therapy is not an exception. It requires a broad range of expertise and in many cases substantial funding from day one.
Takura’s network of ATMP specialists, entrepreneurs, and investors give our inventors the necessary platform to start the company journey. Learn more about our success stories.
We found, we fund and we build
The opportunity in cell- and gene therapeutics
Cell and gene therapeutics is an evolving field of medicine and spans across a range of technologies (e.g. MSCs, iPSs, T-cells, NK Cells) and therapeutic areas. The development of personalized medicine, partly spurred by AI, unleash opportunities for more effective therapies and treatment of previously untreatable conditions.
As the pace of market approvals and commercial roll-outs increase rapidly, cell- and gene therapy, combined with other biologics, are expected to dethrone small molecules as the leading market segment in pharmaceuticals in the near future.